Lyra Therapeutics (LYRA) Misses Q1 EPS by 1c

Lyra Therapeutics (NASDAQ: LYRA) reported Q1 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Lyra Therapeutics (LYRA) click here.

You May Also Be Interested In

• salesforce.com (CRM) Reiterated Market Outperform by Citizens: 50% of Checks Positive
• Bernstein SocGen Group Upgrades Square Enix Holdings (9684:JP) (SQNNY) to Outperform
• UBS Upgrades Drax Group Plc. (DRX:LN) (DRXGY) to Neutral